Recruiting Lung Cancer Studies in Springfield
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated ex...
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with ide...
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squ...
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study is open to adults 18 years and older with advanced or metastatic non-small cell lung cancer. People can join the study if they have tumours with HER2 mutations and have not yet received any...
About Lung Cancer Clinical Trials in Springfield
Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.
There are currently 4 lung cancer clinical trials recruiting participants in Springfield, ILLINOIS. These studies are seeking a combined 2,231 participants. Research is being sponsored by Gilead Sciences, Merck Sharp & Dohme LLC, Boehringer Ingelheim. Clinical trial participation is free and participants receive study-related medical care at no cost.
Lung Cancer Clinical Trials in Springfield — FAQ
Are there lung cancer clinical trials in Springfield?
Yes, there are 4 lung cancer clinical trials currently recruiting in Springfield, ILLINOIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Springfield?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Springfield research site will contact you about next steps.
Are clinical trials in Springfield free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Springfield studies also compensate for your time and travel.
What lung cancer treatments are being tested?
The 4 active trials in Springfield are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.
Data updated March 2, 2026 from ClinicalTrials.gov